Kisqali, Femara Combo Shows Promise in HR+/HER2- Advanced Breast Cancer Patients

Kisqali, Femara Combo Shows Promise in HR+/HER2- Advanced Breast Cancer Patients
The latest results from the Phase 3 MONALEESA-2 study showed that adding Novartis’ Kisqali (ribociclib) to ‎Femara (letrozole) for the treatment of breast cancer in certain postmenopausal women improves the time to disease progression or death by more than nine months, compared to Femara therapy alone. Participants treated with the combo therapy had similar health-related quality of life and no new safety concerns compared to those receiving Femara alone. The study enrolled patients with hormone receptor-positive and HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. The findings were featured in two presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6 in Chicago. The posters were titled “Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)” and “Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.” Kisqali was approved by the U.S. Food and Drug Administration in March of this year as a first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor, such as Femara (also a Novartis product). The MONALEESA-2 Phase 3 trial (NCT01958021) is a
Subscribe or to access all post and page content.

4 comments

  1. Joshalyn Williams says:

    I use Kisquali and Femara – I now have elevated liver and kidney function. My doctor suggests that I reduce the dosage of Femara. I’m thinking I will try Ibrance instead. Femara causes inching. I’m happy that the Kisquali/Femara co-pack has helped me. I don’t think I can take any more damage to the other organs though.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.